| Objective To explore the relationship among anti-mutant citrulline vimentin (MCV) antibody, bone metabolic markers, and disease activity in patients with rheumatoid arthritis (RA). Methods The clinical data and serum of 119 RA patients were collected. Anti-MCV antibody and bone metabolism markers such as RANKL, OPG, and TRACP-5b were detected. The correlation between anti-MCV antibody and bone metabolism markers was analyzed, and the relationship between anti-MCV antibody and disease activity was explored. Results 1) There was no significant correlation between the titer of anti-MCV antibody and the levels of RANKL, TRACP-5b, and RANKL/OPG in RA patients (P>0.05). The correlation between titer of anti-MCV antibody and OPG was positive but with low correlation coefficient (r=0.183, P<0.05). 2) Anti-MCV antibody was positively correlated with DAS28 (r=0.376, P<0.01), ESR (r=0.440, P<0.01), and RF IgM (r=0.376, P<0.01). Conclusion There is no significant correlation between anti MCV antibody and serum markers of bone metabolism, such as TRACP-5b, RANKL, OPG, and RANKL/OPG, suggesting that anti-MCV antibody may not directly participate in the development of RA bone erosion by influencing bone metabolism. There is a positive correlation between anti-MCV antibody and disease activity, suggesting that it may have some value in the evaluation of RA. |